Skip to main content

Advertisement

Log in

Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child

  • Clinical–patient studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Ependymoma is the third most common CNS tumor in children. Neuraxis dissemination at the time of diagnosis is rare and occurs in fewer than 10% of patients. Recent advances in neuroimaging, neurosurgery, and radiation therapy have improved disease control and functional outcomes for children with ependymoma. However, children under the age of 3 years with ependymoma and leptomeningeal spread historically have had worse outcomes. It is not clear if age alone, or a combination of risk factors such us unfavorable location, which may prevent gross total resection, and withholding radiation therapy may have contributed to poor outcomes in younger age groups. The reason for attempting GTR is based on results from retrospective and prospective studies, where the most important prognostic factor is extent of resection. These patients are not candidates for craniospinal irradiation. Therefore, new therapeutic approaches must be attempted. This is a case report of a posterior fossa ependymoma with leptomeningeal dissemination in a two-year-old child, successfully treated with dose intensive chemotherapy and intrathecal liposomal cytarabine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Merchant ME, Fouladi M (2005) Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neurooncol 75:287–299

    Article  PubMed  Google Scholar 

  2. Merchant TE, Mulhern RK, Krasin MJ et al (2004) Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 22:3156–3162

    Article  PubMed  Google Scholar 

  3. Horn BN, Smyth M (2004) Ependymoma. Pediatric CNS tumors. Springer, Berlin, pp 65–81

    Google Scholar 

  4. Wagner LM, Zhou H, Brockmeyer DL, Hedlund GL (2004) Spinal cord schwannomas mimicking drop metastases in a patient with intramedullary ependymoma and neurofibromatosis 2. J Pediatr Hematol Oncol 26:56–59

    Article  PubMed  Google Scholar 

  5. Honda M, So G, Kaminogo M, Abe K, Nagata I (2005) Massive intratumoral hemorrhage of ependymoma of the fourth ventricle. Childs Nerv Syst 21:926–929

    Article  PubMed  Google Scholar 

  6. Fasset DR, Pingree J, Kestle JR (2005) The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg 102(1suppl):59–64

    Google Scholar 

  7. Gallia GL, Burger PC, Suk I et al (2006) Concomitant conus medullaris ependymoma and filum terminale lipoma: case report. Neurosurgery 58:1214–1215

    Article  Google Scholar 

  8. Poltinnikov IM, Merchant TE (2006) CSF cytology has limited value in the evaluation of patients with ependymoma who have MRI evidence of metastasis. Pediatr Blood Cancer 47(2):169–73

    Article  PubMed  Google Scholar 

  9. Duffner P, Horowitz M, Krischer J et al (1993) Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328:1725–1731

    Article  PubMed  CAS  Google Scholar 

  10. Bomgaars L, Geyer JR, Franklin J et al (2004) Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 22:3916–3921

    Article  PubMed  CAS  Google Scholar 

  11. Glantz MJ, Jaeckle KA, Chamberlain MC et al (1999) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5:3394–3402

    PubMed  CAS  Google Scholar 

  12. Murry DJ, Blaney SM (2000) Clinical pharmacology of encapsulated sustained-release cytarabine. Ann Pharmacother 34:1173–1178

    Article  PubMed  CAS  Google Scholar 

  13. Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110–3116

    PubMed  CAS  Google Scholar 

  14. Jaeckle KA, Batchelor T, O’Day SJ et al (2002) An open label trial of sustained-release cytarabine (Depo-Cyt™) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 57:231–239

    Article  PubMed  Google Scholar 

  15. Rueda A, Olmos D, Viciana R, Torres E (2005) Liposomal cytarabine (DepoCyte®) for the treatment of neoplastic meningitis. Clin Transl Oncol 7(6):232–238

    Google Scholar 

  16. Sancho JM, Ribera JM, Romero MJ, Martín-Reina V, Giraldo P, Ruiz E (2006) Compassionate use of intrathecal depor liposomal cytarabine as treatment of central nervous system involvement in acute leukaemia: reporto f 6 cases. E-case Haematologica 91: (ERC)02. (http://www.haematologica.org/online/2006/ECR02/index.html)

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alvaro Lassaletta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lassaletta, A., Perez-Olleros, P., Scaglione, C. et al. Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child. J Neurooncol 83, 303–306 (2007). https://doi.org/10.1007/s11060-006-9327-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-006-9327-6

Keywords

Navigation